A0784812
Atazanavir Sulfate , ≥98% , 229975-97-7
CAS NO.：229975-97-7
Empirical Formula: C38H52N6O7.H2SO4
Molecular Weight: 802.93
MDL number: MFCD08067748
EINECS: 620-495-2
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB31.20 | In Stock |
|
| 10MG | RMB39.20 | In Stock |
|
| 50MG | RMB55.20 | In Stock |
|
| 250MG | RMB79.20 | In Stock |
|
| 1G | RMB111.20 | In Stock |
|
| 5g | RMB399.20 | In Stock |
|
| 25g | RMB1279.20 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 195.0°, or acetone; mp 198-199° (dec) |
| alpha | D22 -46.1° (c = 1 in 1:1 CH3OH/H2O, pH = 2.6) |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C |
| solubility | ≥28.7 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥4.05 mg/mL in EtOH with gentle warming and ultrasonic |
| form | Powder |
| color | White to light yellow |
Description and Uses
Atazanavir (BMS-232632, III), an azapeptide HIV protease inhibitor, has been developed and launched by Bristol-Myers Squibb (BMS), under worldwide license from Novartis, for the treatment of HIV infection. Atazanavir was launched in the US as Reyataz™ in July 2003.
Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM
Safety
| Symbol(GHS) |   GHS08,GHS05 |
| Signal word | Danger |
| Hazard statements | H372-H318 |
| Precautionary statements | P280-P305+P351+P338-P310-P260-P264-P270-P314-P501 |
| Safety Statements | 24/25 |
| HS Code | 29333990 |
